| Theme | Perspective for Chemotherapy in Gastrointestinal Malignancy Based on Current Evidence | |
|---|---|---|
| Title | Systemic Chemotherapy in Patients with Neuroendocrine Neoplasms | |
| Publish Date | 2013/03 | |
| Author | Satoshi Shiba | Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital |
| Author | Chigusa Morizane | Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital |
| Author | Hideyuki Hayashi | Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital |
| Author | Yasunari Sakamoto | Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital |
| Author | Shunsuke Kondo | Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital |
| Author | Hideki Ueno | Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital |
| Author | Takuji Okusaka | Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital |
| [ Summary ] | Neuroendocrine neoplasms (NEN) are rare diseases with limited treatment options available to date, making their treatment extremely difficult. NEN can be classified into two categories：neuroendocrine tumors (NET) G1/G2, or neuroendocrine carcinomas (NEC). For the treatment of NEC, combination chemotherapy regimens consisting of cisplatin and etoposide, or cisplatin and irinotecan (which are conventional treatments for small cell lung carcinoma) have been widely used. For the treatment of NET G1/G2, large prospective, randomized controlled trials have confirmed the efficacy of new drugs, such as sunitinib and everolimus. Interest in the treatment of NET G1/G2 using these new drugs has increased recently. | |